Symbiotec Pharmalab Limited IPO
Offer Date :
Listed At
₹ Offer Price
Lot Size
Subscription
Allotment Date
Listing Date
Ipo Details
Subscription
Lot Distribution
Reservation
Company Financials
₹0 (0.00%)
Premium (ELP)
Symbiotec Pharmalab Limited's is preparing to launch its Initial Public Offering (IPO) with a substantial issue size of TBD. The offering comprises a fresh issue component of TBD, alongside an Offer for Sale (OFS) component of ₹2030.00 Cr from existing shareholders.
The price band for the IPO has been set at TBD, providing investors with a range to place their bids. The minimum investment lot consists of TBD, making it accessible to both retail and institutional investors.
The subscription window for this public offering opens on TBD and will conclude on TBD. Following the subscription period, the share allotment is scheduled for TBD, with the official listing expected to commence on TBD on the NSE, BSE exchange.
Symbiotec Pharmalab IPO About Company
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients, nutritional ingredients, and specialty products for both domestic and international markets. The company focuses on research-based manufacturing, strong quality standards, and sustainable processes, serving industries like pharmaceuticals, nutraceuticals, and wellness with high-quality and innovative products. With over 30 years of experience, it has grown from a small lab-scale steroid API manufacturer into a large, fully integrated company with approvals from global authorities like the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety. As of June 30, 2025, the company operates two large-scale manufacturing facilities with a chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
Symbiotec Pharmalab IPO Strength Factors
- Strong Global Regulatory Approvals : Approved by US FDA, EU-GMP, and other global bodies, ensuring high credibility and export potential.
- Vertically Integrated Manufacturing : Backward-integrated platform with multi-scale production improves cost efficiency and control.
- R&D and Technology Focus : Continuous investment in research enhances innovation and expands product portfolio.
Symbiotec Pharmalab IPO Risk Factors
- High Regulatory Compliance Risk : Pharmaceutical business is highly regulated, and any non-compliance can impact operations.
- Dependence on Key Products : Heavy reliance on steroidal and corticosteroid APIs may limit diversification.
- Capital Intensive Operations : Requires ongoing investment in R&D, facilities, and compliance standards.
Symbiotec Pharmalab IPO Lead Manager(s)
- Jm Financial Limited
- Avendus Capital Private Limited
- Motilal Oswal Investment Advisors Limited
- Nomura Financial Advisory And Securities (India) Private Limited
Symbiotec Pharmalab IPO Promoter(s)
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP
Symbiotec Pharmalab IPO FAQs
Symbiotec Pharmalab Limited IPO subscribed 0 times. The public issue subscribed -- times in the retail category,-- times in QIB, and -- times in the HNI (10+) category byMarch 30, 2026 9:55:58 AM (Day 30).
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
Symbiotec Pharmalab IPO IPO Investor Categories
The offer proceeds will be utilised towards the following investor categories in compliance with SEBI regulations:
Qualified Institutional Buyers (QIB)
Financial Institutions, Banks, FIIs, and Mutual Funds registered with SEBI are called QIBs. In most cases, QIBs represent small investors who invest through mutual funds, ULIP schemes, and pension schemes.
Non-Institutional Investors (NII / HNI)
Retail Individual Investors (HNI), NRIs, Companies, Trusts, etc. who bid for shares worth more than ₹2 lakhs are known as Non-Institutional Bidders. Unlike QIBs, they do not need SEBI registration.
Subcategories of NII:
- sNII (Small NII – bids below ₹10 Lakhs)
For bids between ₹2–10 lakhs. One-third of NII shares are reserved for this category, also known as Small HNI (sHNI).
- bNII (Big NII – bids above ₹10 Lakhs)
For bids above ₹10 lakhs. Two-thirds of NII shares are reserved for this category, also called Big HNI (bHNI).
- sNII (Small NII – bids below ₹10 Lakhs)
Retail Individual Investors (RII)
Individual investors or NRIs who apply up to ₹2 lakhs in an IPO are considered under the RII reserved category.
Employee (EMP)
A category of eligible employees who have a reserved quota in the IPO.
Others
This includes eligible shareholders or other investors with reserved quotas in the IPO.
Symbiotec Pharmalab IPO FAQs
Track all the latest updates and news of IPO.
Om Power Transmission IPO Day 3 update as subscription reaches 71% with GMP and important details
Om Power Transmission IPO opened for subscription on April 9 and will close on April 13, with a price band of ₹166 to ₹175 per share and a lot size of 85 shares. The company raised ₹45.01 crore from anchor investors including Craft Emerging Market Fund PCC, Morgan Stanley Asia (Singapore), and Sunrise Investment Trust. Om Power Transmission is an EPC company focused on power transmission infrastructure with over 14 years of experience. The IPO has reserved...Read More
Om Power Transmission IPO begins today with GMP movement, review, and issue highlights
Om Power Transmission IPO will open for subscription on April 9 and close on April 13, with a price band of ₹166 to ₹175 per share and a lot size of 85 shares. The company has already raised ₹45.01 crore from anchor investors, including Craft Emerging Market Fund PCC, Morgan Stanley Asia (Singapore), and Sunrise Investment Trust. Om Power Transmission is an EPC company focused on power transmission infrastructure with over 14 years of experience. The IPO r...Read More
Emiac Technologies IPO Day 2 update with GMP trends and subscription progress
Emiac Technologies IPO, which opened for subscription on March 27, has seen a weak response so far with around 11% subscription overall. The company raised ₹8.70 crore from anchor investors by allocating shares at ₹98 each. Emiac Technologies is an AI-driven digital solutions firm offering services such as digital marketing, branding, content development, automation, and tech support to help businesses scale efficiently. On Day 1, the IPO was subscribed 0....Read More
Powerica IPO Day 3 update as subscription reaches 3% with latest GMP movement
Powerica IPO, valued at ₹1,100 crore, has seen a muted response with a 3% subscription on Day 2 (March 25). The issue is priced at ₹375–₹395 per share, valuing the company at around ₹5,000 crore. Ahead of the opening, the company raised ₹329.40 crore from anchor investors, including leading mutual funds and insurance companies. The IPO comprises a fresh issue of ₹700 crore and an offer-for-sale of ₹300 crore, with ₹525 crore from the fresh proceeds earmark...Read More
Powerica IPO Day 2 update as subscription remains at 1% with review and GMP details
Powerica IPO, valued at ₹1,100 crore, is open for subscription from March 24 to March 27, with a price band of ₹375–₹395 per share, valuing the company at around ₹5,000 crore. Ahead of the issue, the company raised ₹329.40 crore from anchor investors, including major mutual funds and insurance companies. Powerica operates as a comprehensive power solutions provider, focusing on diesel generator sets (DG sets), medium-speed large generators (MSLG), and rela...Read More
Central Mine Planning IPO Day 1 update as subscription reaches 1% with review and key highlights
The Central Mine Planning and Design Institute (CMPDIL) IPO is open for subscription from March 20 to March 24, 2026, with a price band of ₹163–₹172 per share, valuing the company at around ₹12,280 crore. Entirely an offer-for-sale of 10.71 crore shares by Coal India, the IPO allocates 50% to qualified institutional buyers, 35% to retail investors, and 15% to non-institutional investors, with a lot size of 80 shares. Founded in 1975, CMPDIL offers consulti...Read More
GSP Crop Science IPO opens Day 1 with GMP trend, price band and important details
The IPO of GSP Crop Science Ltd opened for subscription today and will remain open until March 18, 2026. The company has fixed the price band at ₹304 to ₹320 per share and aims to raise ₹400 crore through a combination of fresh issue and offer-for-sale. In the grey market, the shares are currently trading at par with a grey market premium (GMP) of ₹0, indicating neutral sentiment ahead of the issue. By early bidding, the IPO was subscribed 0.01 times overa...Read More
SEDEMAC Mechatronics IPO Day 3 update as subscription reaches 46% with latest GMP trends
SEDEMAC Mechatronics IPO opened for subscription on March 4 and will close on March 6, with a price band of ₹1,287 to ₹1,352 per share, valuing the company at around ₹6,000 crore at the upper band. The IPO is entirely an offer for sale of up to 80,43,300 equity shares by promoters and other investors, so the company will not receive any proceeds from the issue. The Pune-based company designs and manufactures electronic control units (ECUs) used in automoti...Read More
Omnitech Engineering IPO wraps up today with final Day 3 bidding details
Omnitech Engineering Ltd’s ₹583 crore IPO entered its final day of bidding on February 27 after opening on February 25, with the issue comprising a mix of fresh issue and offer-for-sale and proposed to be listed on the BSE and NSE. On Day 3, the IPO was subscribed 15% overall, with the retail portion booked 15%, the NII segment 13%, and the QIB category 13%, indicating muted demand. The grey market premium (GMP) stood at ₹3, suggesting limited listing gain...Read More
Clean Max Enviro IPO sees muted demand on Day 3 with 46% booking and weak GMP signals
Clean Max Enviro Energy Solutions IPO closed its third and final day of bidding on February 25 after being subscribed 45% by the end of Day 2, with the company having already raised ₹921 crore from anchor investors. The IPO is priced at ₹1,000–₹1,053 per share, valuing the company at ₹12,325 crore at the upper band, and comprises a fresh issue of ₹1,200 crore along with an offer-for-sale of ₹1,900 crore by promoters and investors, reduced from the earlier ...Read More
Gaudium IVF IPO Day 3 update as subscription reaches 3.63 times with latest GMP trends
Gaudium IVF & Women Health IPO, which opened on February 20, was subscribed 3.63 times by the close of bidding on February 24, with strong participation from retail and non-institutional investors. The retail portion was subscribed 4.64 times and the NII segment 6.11 times, while QIB participation remained modest at 3%. The ₹165-crore issue, priced at ₹75–79 per share with a lot size of 189 shares, comprises a fresh issue of ₹90 crore and an OFS of ₹75 cro...Read More
Clean Max Enviro IPO opens today with latest GMP, key dates, and subscription details
Clean Max Enviro Energy Solutions IPO will open for subscription on February 23 and close on February 25, with a price band of ₹1,000–1,053 per share, valuing the issue at ₹12,325 crore at the upper end. Ahead of the public launch, the company raised ₹921 crore from anchor investors by allotting 87,46,437 shares at ₹1,053 each, with participation from major domestic and global institutional investors. The IPO comprises a fresh issue of ₹1,200 crore and an ...Read More
Gaudium IVF IPO LIVE updates as GMP signals an 11% listing pop and issue booked 8% so far
Gaudium IVF and Women Health IPO opened for subscription on February 20 and will close on February 24, aiming to raise ₹165 crore. Ahead of the launch, the company secured ₹49.5 crore from anchor investors by allotting 62,65,860 shares at ₹79 per share. The price band for the IPO has been fixed at ₹75–79 per share, valuing the company at around ₹575 crore. The issue comprises a fresh issue of 1.14 crore equity shares and an offer for sale of nearly 95 lakh...Read More
IPO GMP trends for Clean Max Enviro, Shree Ram Twistex, and PNGS Reva Diamond Jewellery in focus
The primary market is set to witness renewed momentum with four mainboard IPOs scheduled to open over the coming days. Gaudium IVF & Women Health IPO will kick off the activity on February 20, followed by Clean Max Enviro Energy Solutions and Shree Ram Twistex on February 23, while PNGS Reva Diamond Jewellery will open on February 24. Clean Max Enviro Energy Solutions has fixed its price band at ₹1,000–1,053 per share and is currently commanding a grey mar...Read More
Aye Finance IPO allotment date in spotlight with fresh GMP trends and status check process
The Aye Finance IPO allotment is set to be finalised on February 12, and investors can check their allotment status through the registrar, Kfin Technologies. The IPO saw a 97% subscription by the end of Day 3, with the QIB portion subscribed 1.50 times, retail investors 77%, and NIIs 5%. The price band was ₹122–129 per share, valuing the company at ₹3,184 crore at the upper end. The ₹1,010-crore issue comprised a fresh issue of ₹710 crore and an OFS of ₹30...Read More
Fractal Analytics IPO sees moderate demand on Day 3 with 20% subscription and GMP trends
The Fractal Analytics IPO has witnessed muted investor interest for the second consecutive day, with the issue subscribed 20% as of February 11. The IPO, which opened on February 9 and closes on February 11, is priced in the range of ₹857–900 per share with a lot size of 16 shares. Retail investors have subscribed 60% of their quota, NIIs 27%, and QIBs 2%. The company has received bids for 36,41,104 shares against 1,85,79,360 shares on offer. The ₹2,834-cr...Read More
Kasturi Metal IPO applicants can check allotment status online this way
The basis of allotment for the Kasturi Metal Composite IPO is likely to be finalised today, Friday, January 30, 2026, after the issue closed on January 29 with strong investor interest and an overall subscription of over 16 times. The ₹17.61-crore IPO was entirely a fresh issue of 28 lakh equity shares, priced in the range of ₹61–64 per share with a lot size of 2,000 shares. As per subscription data, NIIs subscribed their portion 29.06 times, retail invest...Read More
KRM Ayurveda IPO allotment goes live today with latest GMP and expected listing date
The basis of allotment for the KRM Ayurveda IPO is likely to be finalised today, Tuesday, January 27, 2026, after the issue closed on January 24 with a strong subscription of 74.27 times. Once finalised, applicants can check their allotment status on the official NSE website or through the registrar, Skyline Financial Services. The ₹77.49-crore IPO was entirely a fresh issue of 57 lakh equity shares, priced in the range of ₹128–135 per share with a lot siz...Read More
Shadowfax Technologies IPO Day 3 update as subscription reaches 60% with GMP and key dates in focus
Shadowfax Technologies IPO entered Day 3 with moderate investor response, as the issue was subscribed around 60% by the end of Day 2. The Bengaluru-based logistics company opened its IPO on January 20 and will close today, January 22, with a price band of ₹118–124 per share. Ahead of the issue, the company raised ₹856.02 crore from anchor investors. The IPO allotment is expected on January 23, refunds and demat credit are likely on January 27, and the stoc...Read More
Bharat Coking Coal IPO sees strong Day 1 demand at 2.50x subscription; GMP points to a 60% premium
Bharat Coking Coal (BCCL) IPO, the first mainboard public issue of 2026, opened for subscription today, January 9, and will remain open till January 13. The IPO is entirely an offer for sale by Coal India Limited, with a price band of ₹21–₹23 per share and a total issue size of ₹1,071 crore at the upper end. Ahead of the opening, BCCL raised ₹273.1 crore from anchor investors. The issue has been reserved 50% for QIBs, 35% for NIIs, and 15% for retail inves...Read More
Modern Diagnostic IPO ends today as final-day subscription and GMP remain in focus
The Modern Diagnostic IPO, which opened for subscription on December 31, 2025, has seen strong investor demand, with the issue subscribed over 28.77 times by the end of Day 2, driven mainly by robust participation from non-institutional investors and retail bidders. The NII portion was oversubscribed 39.61 times, while retail investors subscribed 33.85 times, and QIBs booked their segment 8.94 times, as per BSE data. Positive sentiment is also reflected in...Read More
Shyam Dhani Industries IPO sees strong Day 3 momentum as GMP indicates a 90% listing gain
Shyam Dhani Industries IPO, which opened on December 22 and closes on December 24, is witnessing strong investor demand on Day 3, with overall subscription crossing 360 times by mid-morning. The SME IPO has attracted heavy interest across categories, supported by a sharp rise in grey market premium to ₹62, indicating a potential listing premium of around 89% over the upper price band of ₹70. Ahead of the issue, the company raised ₹10.92 crore from anchor i...Read More
Gujarat Kidney IPO opens today with GMP, subscription status, price band, and key details
Gujarat Kidney & Super Speciality IPO opened for subscription on December 22 and will close on December 24, with a price band of ₹108–114 per share, aiming to raise ₹250.80 crore through a completely fresh issue of 2.20 crore shares. The company plans to use the proceeds for hospital acquisitions in Ahmedabad, equity investment in its subsidiary, a new hospital project in Vadodara, purchase of robotics equipment, debt repayment, and general corporate purpo...Read More
ICICI Prudential AMC IPO allotment LIVE update as status is released; GMP indicates a 17% listing premium
ICICI Prudential AMC IPO allotment has been finalised, and market attention has now shifted to the company’s listing scheduled for December 19. The ₹10,602.65-crore public issue received an overwhelming response, garnering bids of nearly ₹3 lakh crore and ending with an overall subscription of 39.17 times, led by strong demand from institutional investors. Priced in the range of ₹2,061 to ₹2,165 per share, the IPO was entirely an offer for sale by the prom...Read More
ICICI Prudential AMC IPO allotment date in focus with GMP and status check guide
The ICICI Prudential AMC IPO allotment is expected today after a strong response from investors, with the issue subscribed over 39 times across three days of bidding. The IPO is priced at ₹2,061–2,165 per share, entirely an offer for sale worth ₹10,602.65 crore. The grey market premium (GMP) stands at ₹304 today, indicating bullish sentiment. Applicants can check their allotment status online via the BSE website or KFintech portal using their Application N...Read More
ICICI Prudential AMC IPO sees steady demand on Day 3 with 2.5x subscription and GMP check
ICICI Prudential AMC IPO, which opened on December 12, 2025, is closing today, December 16, 2025, and has seen steady investor interest, with the issue subscribed 2.51 times by 10:15 am on Day 3, driven mainly by strong participation from non-institutional and qualified institutional investors, while the retail segment remains moderately subscribed. The IPO is priced in the range of ₹2,061–2,165 per share and is entirely an offer for sale aggregating ₹10,6...Read More
ICICI Prudential AMC IPO Day 2 update covering GMP trends, subscription status, and review
ICICI Prudential AMC IPO opened for subscription on December 12, 2025, and will close on December 16, 2025, with a price band fixed at ₹2,061 to ₹2,165 per share. The ₹10,602.65 crore issue is entirely an Offer for Sale (OFS), meaning the proceeds will go to existing shareholders and not to the company. In the grey market, ICICI Prudential AMC shares are trading at a premium of around ₹280, indicating strong listing expectations despite moderate subscripti...Read More
Corona Remedies IPO Allotment LIVE with GMP hinting at a 29% listing gain and online status tracking steps
The Corona Remedies IPO allotment has been finalised after witnessing an exceptional overall subscription of 137 times, driven by strong demand from QIBs at 278.52 times, NIIs at 208.88 times, and retail investors at 28.73 times. The ₹655.37-crore issue, priced between ₹1,008 and ₹1,062 per share, attracted heavy bidding, and investors can now check their allotment status on the BSE or Bigshare Services website. Corona Remedies, headquartered in Ahmedabad,...Read More
Corona Remedies IPO allotment scheduled for today along with status, GMP, and expected listing info
Corona Remedies IPO, valued at ₹655.37 crore and priced between ₹1,008–1,062 per share with a lot size of 120 shares, received bids for 62.65 crore shares against 45.72 lakh shares on offer. QIBs led the demand with subscriptions of 278.52 times, followed by NIIs at 208.88 times, while the retail category was subscribed 28.73 times. With the bidding now closed, investors are awaiting the allotment outcome, which is expected later today. Once finalised, all...Read More
Aequs IPO maintains strong momentum on Day 3 with 16.45x subscription and GMP suggesting a 33% gain
Aequs Ltd’s IPO entered Day 3 on a strong note after recording 11.10 times subscription by the end of Day 2. The issue, which opened on December 3 and closes on December 5, has a price band of ₹118–124 per share, giving the company a valuation of over ₹8,300 crore. The IPO GMP has risen to ₹41 today, indicating an estimated listing price of around ₹165 per share, nearly 33 percent above the upper price band. The company, known for aerospace manufacturing, ...Read More
Symbiotec Pharmalab Limited was listed on the stock exchange on . The IPO was subscribed 0x. The last GMP for Symbiotec Pharmalab Limited IPO was ₹0, updated on March 30, 2026 9:55:58 AM (Day 30). As per the last GMP, the expected profit/loss for the IPO was ₹0.
The IPO allotment has not been confirmed yet. To check your status , Symbiotec Pharmalab IPO Allotment Status Please Click Here.
PAN List
To access the Quick Allotment Checker, please log in to your account.
The basis of allotment for Symbiotec Pharmalab Limited IPO is available now.
To check Symbiotec Pharmalab Limited IPO allotment status, follow the steps below :
- Click on the below allotment status check button.
- Select Company Name.
- Enter your PAN Number, Application Number or DP Client ID (Anyone).
- Click on Search.
A category of eligible shareholders or other investors who have a reserved quota in the IPO.
If you have any concerns or queries about the allotment status, contact the registrar using the details below. Contact the registrar via their official website.